Arthex Biotech Announces Closing Of €42 M Series B Financing To Advance Atx-01, Its Novel Treatment For Myotonic Dystrophy Type 1 (Dm1)
Amount Raised
€42 Million
Round Type
Series B
Investors
Description
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing round led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Hadean Ventures, and Sound Bioventures. Existing investors Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI) through its Innvierte program, also participated in the financing.
Quick answer
ARTHEx Biotech raised €42 Million in a Series B round, dated May 3, 2023. Investors: The Centre For The Development Of Industrial Technology, Cdti, Ad Bio Partners, Invivo Capital, Sound Bioventures, Hadean Ventures, European Innovation Council and Columbus Venture Partners.
- How much did ARTHEx Biotech raise?
- ARTHEx Biotech raised €42 Million in a Series B round on May 3, 2023.
- Who invested in ARTHEx Biotech?
- The Centre For The Development Of Industrial Technology, Cdti, Ad Bio Partners, Invivo Capital, Sound Bioventures, Hadean Ventures, European Innovation Council and Columbus Venture Partners are named as investors in this round.
- What does ARTHEx Biotech do?
- ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical..
- Where is ARTHEx Biotech based and how big is it?
- Fundz records about 2 employees.
- Who are the decision-makers at ARTHEx Biotech?
- Fundz holds 1 contact at ARTHEx Biotech. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as ARTHEx Biotech that raised within 45 days of this round, from Fundz verified event records.
- Zucara Therapeutics raised an undisclosed amount (Funding Round) on June 15, 2023.
- Metagen Therapeutics raised an undisclosed amount (Series A) on June 15, 2023.
- Eccogene raised $25M (Series B) on June 12, 2023.
- Kate Therapeutics raised $51M (Series A) on June 8, 2023.
- Acepodia raised $100M (Series D) on June 6, 2023.
- Alkeus Pharmaceuticals raised $150M (Series B) on June 5, 2023.
Who to call at ARTHEx Biotech, and when
A new round usually means ARTHEx Biotech is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ARTHEx Biotech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ARTHEx Biotech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ARTHEx Biotech. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ARTHEx Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansARTHEx Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.